| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| urelumab | co-stimulatory molecule 4-1bb | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] B-Cell Lymphomas[MeSHID:D016393] melanoma[MeSHID:D008545] |
95.48 | phase 2 | antibody |
| urelumab | co-stimulatory molecule 4-1bb | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] B-Cell Lymphomas[MeSHID:D016393] melanoma[MeSHID:D008545] |
95.48 | phase 2 | unknown |
| urelumab | tumor necrosis factor receptor superfamily member 9 | biotech | NA | drugbank , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] B-Cell Lymphomas[MeSHID:D016393] melanoma[MeSHID:D008545] |
95.48 | investigational | antibody |
| urelumab | co-stimulatory molecule 4-1bb | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] B-Cell Lymphomas[MeSHID:D016393] melanoma[MeSHID:D008545] |
95.48 | phase 2 | agonist |
| urelumab | tumor necrosis factor receptor superfamily member 9 | biotech | NA | drugbank , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] B-Cell Lymphomas[MeSHID:D016393] melanoma[MeSHID:D008545] |
95.48 | investigational | unknown |
| urelumab | tumor necrosis factor receptor superfamily member 9 | biotech | NA | drugbank , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] B-Cell Lymphomas[MeSHID:D016393] melanoma[MeSHID:D008545] |
95.48 | investigational | agonist |
| click here to return to the previous page | ||||||||